$149.92▴ 2.45%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
Fair value
Fairly valued
Trading right around our fair-value range
Value-trap risk
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Gilead Sciences, Inc.'s earnings-quality signal is not available yet.
Key numbers
Recent news
Sentiment · last 30 days9 articles
2 bullish7 neutral0 bearish
Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH?
Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP
Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYHCo-development Deals in Pharmaceuticals and Biotechnology 2016-2026 | Pharmaceutical Co-Development Deals Reshape R&D Strategies as Companies Share Risk, Costs and Commercial Opportunities
Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?